Company Overview

Balchem Corporation is a publicly traded specialty ingredients company that develops, manufactures, and markets nutritional and functional products for human nutrition, animal nutrition, and industrial specialty applications. The company operates within the broader specialty chemicals, nutrition, and health ingredients industries, with a focus on scientifically supported, value-added formulations rather than commodity chemicals.

The company’s primary revenue drivers are its Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products business segments, which together serve food and beverage manufacturers, dietary supplement brands, animal feed producers, and select industrial customers. Balchem is known for its proprietary encapsulation and chelation technologies, which are designed to improve ingredient stability, bioavailability, and handling. Founded in 1967, the company has evolved from a specialty chemical producer into a nutrition-focused ingredients supplier through sustained organic growth and targeted acquisitions.

Business Operations

Balchem reports three core operating segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. The Human Nutrition & Health segment supplies minerals, vitamins, and specialty nutrients used in dietary supplements, functional foods, beverages, and medical nutrition products. The Animal Nutrition & Health segment provides nutritional solutions such as choline chloride, chelated minerals, and encapsulated nutrients for livestock and companion animal feed. The Specialty Products segment serves industrial markets with performance gases and chemicals, including products used in medical imaging, sterilization, and manufacturing processes.

Operations span both domestic and international markets, supported by proprietary manufacturing processes and intellectual property related to nutrient delivery systems. Balchem conducts business through a network of wholly owned subsidiaries, including Albion Minerals, a key contributor to its chelated mineral portfolio, and Kappa Bioscience, which expanded the company’s presence in vitamin K2 for human health applications. Revenue is generated through long-term customer relationships, formulation expertise, and regulatory-compliant production capabilities.

Strategic Position & Investments

Balchem’s strategic direction emphasizes growth in science-based nutrition, expansion of higher-margin human health ingredients, and continued innovation in nutrient delivery technologies. The company has invested heavily in research and development to support differentiated products with documented efficacy and regulatory acceptance, particularly in dietary supplements and functional nutrition.

Strategic acquisitions have played a significant role in strengthening Balchem’s portfolio, including the acquisitions of Albion Minerals and Kappa Bioscience, which added proprietary mineral chelation and vitamin K2 technologies, respectively. The company continues to invest in emerging health and wellness trends, including condition-specific nutrition, bioavailable minerals, and clean-label formulations, while maintaining disciplined capital allocation and balance sheet management.

Geographic Footprint

Balchem is headquartered in North America, with its corporate headquarters located in Montvale, New Jersey. The company operates manufacturing facilities and technical centers across the United States and maintains a significant commercial presence in Europe, Asia, and Latin America through subsidiaries and distribution partners.

Its global footprint enables Balchem to serve multinational customers and participate in international nutrition and feed markets, while also supporting region-specific regulatory and formulation requirements. International operations contribute meaningfully to revenue, particularly within human nutrition and animal health markets in developed and emerging economies.

Leadership & Governance

Balchem is led by an experienced executive team with a focus on operational excellence, scientific innovation, and disciplined growth. The company’s leadership emphasizes long-term value creation through investment in technology, quality systems, and customer partnerships, supported by a governance framework aligned with public company best practices.

Key executives include:

• Theodore L. Harris – President and Chief Executive Officer
• Frank A. Fertitta – Executive Vice President and Chief Financial Officer
• Patrick Mulcahy – Chief Operating Officer
• Kirk L. Schaefer – Senior Vice President, Human Nutrition & Health
• Scott M. Colby – Senior Vice President, Animal Nutrition & Health

The board of directors provides oversight on strategy, risk management, and capital allocation, with leadership continuity reflecting Balchem’s emphasis on measured expansion and sustainable performance.